Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Xu, Jian-Ming"" wg kryterium: Autor


Wyświetlanie 1-13 z 13
Tytuł :
Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms.
Autorzy :
Han D; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China.
Li YL; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China.
Zhou ZW; Department of Gastric and Pancreatic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Yin F; Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
Chen J; Department of Gastroenterology, The First Affiliated Hospital Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
Liu F; Department of Gastroenterology, China-Japan Friendship Hospital, Beijing 100029, China.
Shi YF; Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Wang W; Department of Gastric and Pancreatic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Zhang Y; Department of Gastroenterology, The First Affiliated Hospital Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
Yu XJ; Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xu JM; Department of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing 100071, China.
Yang RX; Second Department of Internal Medicine, Yunnan Tumor Hospital, Kunming 650118, Yunnan Province, China.
Tian C; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China.
Luo J; Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China.
Tan HY; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China. .
Pokaż więcej
Źródło :
World journal of gastroenterology [World J Gastroenterol] 2021 Jun 07; Vol. 27 (21), pp. 2895-2909.
Typ publikacji :
Journal Article
MeSH Terms :
Neuroendocrine Tumors*/pathology
Stomach Neoplasms*/epidemiology
Stomach Neoplasms*/pathology
Aged ; China/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł :
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
Autorzy :
Li YH; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Qiu MZ; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xu JM; Department of Oncology, 307 Hospital of the People's Liberation Army, Beijing, China.
Sun GP; Department of Oncology, The First Affiliated Hospital of AnHui Medical University, Hefei, China.
Lu HS; Department of General Surgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, China.
Liu YP; The Second Lab of Cancer Research Institute, The First Hospital of China Medical University, Shenyang, China.
Zhong MZ; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhang HL; Department of Oncology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Yu SY; Department of Oncology, Tongji Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Li W; Stem Cell and Cancer Center, First Affiliated Hospital, Jilin University, Changchun, Jilin, China.
Hu XH; Department of Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
Wang JJ; Department of Oncology, Changzheng Hospital, Shanghai, China.
Cheng Y; Department of Oncology, Tumor Hospital of Jilin Province, Changchun, China.
Zhou JT; Department of Oncology, Tumor Hospital of Hunan Province, Changsha, China.
Guo ZQ; Department of Oncology, Tumor Hospital of Fujian Province, Fuzhou, China.
Guan ZG; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Xu RH; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Pokaż więcej
Źródło :
Oncotarget [Oncotarget] 2015 Oct 27; Vol. 6 (33), pp. 35107-15.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Esophagogastric Junction/*pathology
Stomach Neoplasms/*drug therapy
Adenocarcinoma/mortality ; Adult ; Aged ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Disease-Free Survival ; Drug Combinations ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Pilot Projects ; Stomach Neoplasms/mortality ; Tegafur/administration & dosage ; Tegafur/adverse effects
Czasopismo naukowe
Tytuł :
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Autorzy :
Satoh T; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Xu RH; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Chung HC; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Sun GP; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Doi T; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Xu JM; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Tsuji A; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Omuro Y; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Li J; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Wang JW; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Miwa H; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Qin SK; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Chung IJ; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Yeh KH; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Feng JF; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Mukaiyama A; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Kobayashi M; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Ohtsu A; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan.
Bang YJ; Taroh Satoh, Kinki University School of Medicine, Osaka; Toshihiko Doi and Atsushi Ohtsu, National Cancer Center Hospital East, Chiba; Akihito Tsuji, Kochi Health Sciences Center, Kochi; Yasushi Omuro, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Akihira Mukaiyama and Mikiro Kobayashi, GlaxoSmithKline, Tokyo; Hiroto Miwa, Hyogo College of Medicine, Hyogo, Japan; Rui-Hua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Guo-Ping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Jian-Ming Xu, 307 Hospital of the People's Liberation Army; Jin-Wan Wang, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing; Jin Li, Fudan University Cancer Hospital, Shanghai; Shu-Kui Qin, People's Liberation Army 81 Hospital; Ji-Feng Feng, Cancer Hospital of Jiangsu Province, Nanjing, People's Republic of China; Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yung-Jue Bang, Seoul National University College of Medicine, Seoul; Ik-Joo Chung, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea; and Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan. .
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Jul 01; Vol. 32 (19), pp. 2039-49. Date of Electronic Publication: 2014 May 27.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Asian Continental Ancestry Group*/genetics
Asian Continental Ancestry Group*/statistics & numerical data
Antineoplastic Agents, Phytogenic/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*analysis
Paclitaxel/*therapeutic use
Receptor, ErbB-2/*analysis
Stomach Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Agents, Phytogenic/administration & dosage ; Area Under Curve ; Biomarkers, Tumor/genetics ; Drug Administration Schedule ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Kaplan-Meier Estimate ; Lapatinib ; Male ; Middle Aged ; Odds Ratio ; Paclitaxel/administration & dosage ; Pilot Projects ; Quinazolines/administration & dosage ; Receptor, ErbB-2/genetics ; Stomach Neoplasms/chemistry ; Stomach Neoplasms/epidemiology ; Stomach Neoplasms/pathology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Autorzy :
Shen L; Department of Gastroenterology, Peking University Cancer Hospital & Institute, Beijing 100142, China. />Xu JM
Feng FY
Jiao SC
Wang LW
Li J
Guan ZZ
Qin SK
Wang JJ
Yu SY
Wang YJ
Jin YN
Tao M
Zheng LZ
Pan LX
Pokaż więcej
Źródło :
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2013 Apr; Vol. 35 (4), pp. 295-300.
Typ publikacji :
Clinical Trial, Phase III; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Esophagogastric Junction*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Esophageal Neoplasms/*drug therapy
Receptor, ErbB-2/*metabolism
Stomach Neoplasms/*drug therapy
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Capecitabine ; China ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Esophageal Neoplasms/pathology ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Fluorouracil/analogs & derivatives ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Nausea/chemically induced ; Neoplasm Staging ; Neutropenia/chemically induced ; Remission Induction ; Retrospective Studies ; Stomach Neoplasms/pathology ; Survival Rate ; Trastuzumab ; Vomiting/chemically induced
Czasopismo naukowe
Tytuł :
Significance of elevated levels of collagen type IV and hyaluronic acid in gastric juice and serum in gastric cancer and precancerous lesion.
Autorzy :
Ruan HL; Department of Gastroenterology, First Affiliated Hospital of Anhui Medical University, Key Laboratory of Digestive Disease of Anhui Province, Hefei, 230022, Anhui Province, China. />Hong RT
Xie HJ
Hu NZ
Xu JM
Zhang W
Pokaż więcej
Źródło :
Digestive diseases and sciences [Dig Dis Sci] 2011 Jul; Vol. 56 (7), pp. 2001-8. Date of Electronic Publication: 2011 Jan 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*analysis
Carcinoma/*diagnosis
Collagen Type IV/*analysis
Gastric Juice/*chemistry
Hyaluronic Acid/*analysis
Precancerous Conditions/*diagnosis
Stomach Neoplasms/*diagnosis
Adult ; Aged ; Aged, 80 and over ; Basement Membrane/chemistry ; Basement Membrane/enzymology ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/metabolism ; Cathepsin D/metabolism ; Collagen Type IV/blood ; Collagen Type IV/metabolism ; Female ; Humans ; Hyaluronic Acid/blood ; Hyaluronic Acid/metabolism ; Lymphatic Metastasis ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
[The present understanding of medicinal treatment of stomach cancer].
Autorzy :
Xu JM
Pokaż więcej
Źródło :
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2008 Aug; Vol. 30 (8), pp. 635-7.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Stomach Neoplasms/*drug therapy
Chemotherapy, Adjuvant ; Genomics ; Humans ; Neoadjuvant Therapy ; Neoplasm Staging ; Proteomics ; Quality of Life ; Salvage Therapy ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Survival Rate
Czasopismo naukowe
Tytuł :
[Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Autorzy :
Yang JL; Department of Oncology, General Hospital of People's Liberation Army, Beijing 100853, China.
Jiao SC
Dai GH
Li F
Zhao H
Li Y
Xu JM
Liu W
Zhang Y
Niu RG
Xie XD
Song SP
Zhang FC
Lu HS
Wang J
Pokaż więcej
Źródło :
Zhonghua yi xue za zhi [Zhonghua Yi Xue Za Zhi] 2008 May 27; Vol. 88 (20), pp. 1412-4.
Typ publikacji :
English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Stomach Neoplasms/*drug therapy
Adolescent ; Adult ; Aged ; Cisplatin/administration & dosage ; Female ; Fluorouracil/administration & dosage ; Humans ; Middle Aged ; Oxonic Acid/administration & dosage ; Pyridines/administration & dosage ; Single-Blind Method ; Stomach Neoplasms/pathology ; Tegafur/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
H pylori status and angiogenesis factors in human gastric carcinoma.
Autorzy :
Mangia A; Clinical Experimental Oncology Laboratory, National Cancer Institute, Via Amendola 209, Bari 70126, Italy.
Chiriatti A
Ranieri G
Abbate I
Coviello M
Simone G
Zito FA
Montemurro S
Rucci A
Di Leo A
Tommasi S
Berloco P
Xu JM
Paradiso A
Pokaż więcej
Źródło :
World journal of gastroenterology [World J Gastroenterol] 2006 Sep 14; Vol. 12 (34), pp. 5465-72.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Helicobacter Infections/*complications
Helicobacter pylori/*pathogenicity
Neovascularization, Pathologic/*physiopathology
Stomach Neoplasms/*blood supply
Stomach Neoplasms/*microbiology
Adult ; Aged ; Aged, 80 and over ; Antigens, Bacterial/genetics ; Antigens, Bacterial/metabolism ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Female ; Gene Expression Regulation, Bacterial ; Gene Expression Regulation, Neoplastic ; Helicobacter Infections/genetics ; Helicobacter Infections/metabolism ; Helicobacter pylori/genetics ; Helicobacter pylori/immunology ; Humans ; Immunoglobulin G/blood ; Immunoglobulin G/genetics ; Male ; Microcirculation ; Middle Aged ; Neovascularization, Pathologic/genetics ; Neovascularization, Pathologic/metabolism ; Receptors, Vascular Endothelial Growth Factor/genetics ; Receptors, Vascular Endothelial Growth Factor/metabolism ; Stomach Neoplasms/genetics ; Stomach Neoplasms/metabolism ; Thymidine Phosphorylase/genetics ; Thymidine Phosphorylase/metabolism ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Vascular Endothelial Growth Factor A/blood ; Vascular Endothelial Growth Factor A/metabolism
Czasopismo naukowe
Tytuł :
Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma.
Autorzy :
Shi H; Department of Gastroenterology, the First Affiliated Hospital, Anhui Medical University, Hefei 23022, Anhui Province, China. />Xu JM
Hu NZ
Xie HJ
Pokaż więcej
Źródło :
World journal of gastroenterology [World J Gastroenterol] 2003 Jul; Vol. 9 (7), pp. 1421-6.
Typ publikacji :
Journal Article
MeSH Terms :
Isoenzymes/*biosynthesis
Prostaglandin-Endoperoxide Synthases/*biosynthesis
Stomach Neoplasms/*metabolism
Stomach Neoplasms/*mortality
Vascular Endothelial Growth Factor A/*biosynthesis
Aged ; Cyclooxygenase 2 ; Female ; Humans ; Immunohistochemistry ; Male ; Membrane Proteins ; Microcirculation ; Middle Aged ; Multivariate Analysis ; Neovascularization, Pathologic/metabolism ; Neovascularization, Pathologic/mortality ; Neovascularization, Pathologic/pathology ; Predictive Value of Tests ; Prognosis ; Retrospective Studies ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Survival Rate
Czasopismo naukowe
    Wyświetlanie 1-13 z 13

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies